secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001104659-23-127783
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia wins Federal Circuit ruling affirming invalidation of United Therapeutics' '793 patent
--------------------------------------------------------------------------------

- Federal Circuit upheld PTAB decision finding all claims of U.S. Patent No. 10,716,793 unpatentable.
- Liquidia will immediately seek to set aside the District Court injunction and pursue final FDA approval of YUTREPIA.
- FDA PDUFA goal date for PH-ILD indication is January 24, 2024.
- CEO Roger Jeffs stated company now has rulings that YUTREPIA does not infringe any valid claim in three initially asserted patents.
- Liquidia will also seek dismissal of related claims in second Hatch-Waxman lawsuit and defend against new '327 patent allegations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923127783/0001104659-23-127783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923127783/tm2333396d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-127783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer